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Breast cancer is one of the most frequent and malignant types of cancer in women, with an increasing morbidity 
and mortality rate. Treatment of triple negative breast cancer remains a challenge, since the efforts made with 
targeted therapies were ineffective. MicroRNAs (miRNAs) could play important roles in cancers via post-
transcriptionally regulating target genes via binding to specific sequences in the 3'-UTR of downstream target 
genes. In the present study, the effect of miR-382 on the biological behaviors of triple negative breast cancer 4T1 
cells is investigated. The expression of PGC-1α in the 4T1 cells transfected with miR-382 mimics was significantly 
decreased, while it was obviously increased after transfection with anti-miR-382. Moreover, the cell migration 
and proliferation activity were significantly increased in the miR-382+pCDNA-PGC-1α group when compared 
with the control+pCDNA3.1 group. However, the antitumor effect of miR-382 was blocked by overexpression of 
PGC-1α. Our results showed that miR-382 inhibits the proliferation and metastasis of 4T1 cells by down-
regulating PGC-1α, suggesting miR-382 might be a therapeutic target in triple negative breast cancer. 
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Triple Negative Breast Cancer (TNBC) is a special type of 
breast cancer, estrogen receptor (ER), progesterone receptor 
(PR) and human epidermal growth factor receptor 2 (Her-2) in 
TNBC ) are negative expression. Such breast cancer has the 
characteristics of high recurrence rate, easy metastasis, and 
poor treatment and prognosis [1]. 
PGC-1α is one of the subtypes of the PGC-1 family and is 
a coactivator of peroxisome proliferator-activated receptor γ 
(PPARγ) [2]. It is mainly found in cells with high energy, high 
metabolism and containing more mitochondria. Studies have 
shown that PGC-1α promotes distant metastasis of cancer cells 
by enhancing mitochondrial function in invasive breast cancer 
[3]. Many microRNAs (miRNAs) upstream of PGC-1α are 
involved in the regulation of PGC-1α expression. We found 
through online software predictive analysis (www.micro-
rna.org) that there are 11 potential miRNA binding sites in the 
3'UTR untranslated region of mouse PGC-1α. miRNAs are 
small non-coding RNAs containing approximately 20-22 
nucleotides that specifically promote or inhibit target 
messenger mRNA by specifically binding to the 3' 
untranslated region (3'-UTR) of the target messenger RNA 
(mRNA). Translation of 3'-UTR promotes and inhibits the 
action of cancer cells. Many studies have shown that miRNAs 
play an important role in the process of cell growth, including 
metabolism, homeostasis, proliferation and apoptosis [4].  
Studies have found that the expression level of miR-382 is 
closely related to the prognosis of breast cancer [5]. Our 
previous study found that tumor-associated macrophages 
(TAMs) inhibit the expression of PGC-1α by intracellular 
miR-382, thereby preventing M2-type differentiation of 
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TAMs and subsequent PGC-1α-mediated oxidation. Inhi-
bition of tumor environmental metabolic reprogramming and 
metastasis of cancer cells [6-7]. However, whether miR-382, 
which exists in breast cancer cells itself, regulates the transfer 
of breast cancer cells by regulating PGC-1α is still unclear. 
This study focused on the effects of miR-382 on PGC-1α and 
cell biological characteristics in TNBC 4T1 cell line, in order 
to provide more experimental data for the diagnosis and 
treatment of TNBC. 
Materials and methods 
Main reagents 
Plasmid, 4T1 cell line, 293T cell line were purchased from 
the Shanghai Institute of Life Sciences Cell Bank of Chinese 
Academy of Sciences; pcDNA3.1 and pcDNA3.1- PGC-1α 
plasmid (#1026, addgene, USA); pMIR-REPORT (Applied 
Biosystems Inc); miR-382 and Anti-miR-382 (#4464066, 
Invitrogen) and Control miR (#4464058, Invitrogen); Reverse 
Transcription Kit and qRT-PCR Kit (TaKaRa); GAPDH 
(Biyuntian); Anti-pgc1 antibody (Abcam), Western blot other 
related reagents (Dingguo company); plasmid large 
endotoxin-free kit (QIAGEN), luciferase assay kit (promega), 
opti-MEM (TBD), TransIT-293 Transfection Reagent 2700 
(Mirus Bio LLC), Transwell chamber (pore size 0.4 m) was 
purchased from Corning Corporation, PROMEGA 20/20 
LUMINOMETER GLOMAX (promega). Cell culture flask, 
cell culture plate (Corning), DMEM high glucose medium, 
RPMI 1640 medium and fetal bovine serum (GIBCO); 
BB5060 UV carbon dioxide incubator (Heraeus), inverted 
phase contrast microscope (Leica). 
Cell culture 
4T1 cells were cultured in RPMI1640 containing 10% fetal 
bovine serum (FBS), and 1% penicillin-streptomycin double 
antibody, and cultured in an incubator at 37 °C, 5% CO2, and 
saturated humidity. 293T cells were cultured in DMEM 
containing 10% fetal bovine serum (FBS) and cultured in an 
incubator at 37 °C, 5% CO2, and saturated humidity. 
Animal and grouping 
40 SPF grade BALB/c female mice in 6-8 weeks old and 
18~20 g  were raised in the Animal Experimental Center of 
Gannan University. Experimental group design as following: 
control group: control miR transfected 4T1 cells; miR-382 
experimental group: miR-382mimics transfected 4T1 cells; 
anti-miR-382 experimental group: miR-382 inhibitory probe 
anti-miR-382 Dye to 4T1 cells. Each set of experiments was 
repeated 3 times. 
Cell luciferase assay 
Wild control group: co-transfected 4T1 cells with control 
miR and 3'-UTR reporter plasmid containing core 
complementary sequence; wild experimental group: co-
transfected miR-382 mimics with 3'-UTR reporter plasmid 
containing core complementary sequence 4T1 Cells; mutant 
control group: co-transfected the control miR with the 3'-UTR 
reporter plasmid containing the mutated core complement of 
the 4T1 cell; mutant experimental group: the miR-382 mimics 
and the 3'-UTR containing the mutated core complement The 
reporter plasmid was co-transfected into 4T1 cells. Each set of 
experiments was repeated 3 times. 
Biological characteristics of 4T1 cells 
Control miR pCDNA3.1 group: control miR pCDNA3.1 
co-transfected into 4T1 cells; control miR pCDNA-PGC-1α 
group: control miR pCDNA-PGC-1α co-transfected into 4T1 
cells; miR-382+pCDNA3. Group 1: miR-382 mimics and 
pCDNA3.1 were co-transfected into 4T1 cells; miR-
382+pCDNA-PGC-1α. Group 2: miR-382 mimics and 
pCDNA-PGC-1α were co-transfected into 4T1 cells. Each set 
of experiments was repeated 3 times. 
qRT-PCR 
Each group of cells was collected, RNA was extracted using 
TRIzol, and then cDNA was synthesized using reverse 
transcription kit and then subjected to qRT-PCR detection. 
Mouse PGC-1α mRNA PCR primer: sense strand: 5'-
AACCACACCCACAGGATCAGA-3'; antisense strand: 5 '-
TCTTCGCTTTATTGCTCCATGA-3'. The reaction condi-
tions and relative expression levels of RNA were calculated in 
the same study as previous studies [6]. 
Western blot 
The BCA protein was quantified after each group of cells 
was collected, and the protein concentration was determined. 
The specific method is reported in the literature [6]. 
Dual luciferase assay 
Target Scan and PicTar software were used to predict miR-
382 target genes to screen for target genes with consistent 
predictions. Using the Target Scan and NCBI databases, we 
designed the PGC-1 3'-UTR PCR primer using Primer5 
software: (sense strand: 5'-GCAAGCTTCGTGTTCCCAG-
GCTGAGGAATG-3' antisense strand: 5'-CGGAGCT-
CGTCTGCTCCTCAGAAGGAGCCA-3'. Using DNA as a 
template PCR amplification, synthesis of 3'-UTR sequence 
fragment amplification products identified by 2% agarose gel 
electrophoresis, PCR recovery of PCR products, selection of 
HindIII/SacI restriction enzymes added to the 5' end of the 
primer, plus base GC The plasmid was incubated overnight at 
37 °C. The plasmid and the desired fragment were purified,   
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Figure 1. Effect of potential miRNA on the expression of PGC-1α 
mRNA by online prediction. * P < 0.05, compared to the control. 
 
 
Figure 2．Effect of overexpression of miR-382 on the expression of 
PGC-1α protein. The expression of PGC-1α protein is increased after 
treatment with miR-382. 
 
and T4 ligase was added to react at 4 °C overnight, and then 
the ligation product was transformed into competent cells. 
Then, single colonies were picked for culture, and plasmid 
extraction reagent was used. The plasmid was extracted and 
verified by sequencing. The sequencing was performed by 
Shanghai Jikai Co. After sequencing, the plasmid was 
extracted, and 293T cells were cultured to logarithmic growth 
phase, and seeded in 24-well plates. The number of cells per 
well was 5×104, transfected with Mirus. Reagent transfection, 
according to the experimental group requirements, take 
control, normal or mutant plasmid, diluted with opti-MEM 50 
μL, and gently mixed with miR382; opti-MEM 50 μL added 
Mirus 2 μL. Incubated for 5 min at room temperature; mix the 
above two steps of the solution and incubate at room 
temperature for 20 min; add the mixture to the 24-well plate 
once and mix well; after incubating for 5-6 h in the incubator, 
replace with normal medium before a luciferase assay was 
performed. 
Transwell assay 
MiR-382 or control miR was co-transfected into 4T1 cells 
with pCDNA3.1 or pCDNA-PGC1α, respectively, and the 
cells were in logarithmic growth phase, washed twice with D-
Hanks solution, and then serum-free RPMI1640 medium was 
added. Cells starved for 12 h. The cell suspension was 
prepared by adding 0.25% trypsin and adding serum-free 
RPMI1640 medium to adjust the cell density to 1.33×106 /mL. 
500 μL of complete medium containing 20% FBS was added 
to the Transwell plate and the chamber was placed in the plate. 
200 μL of the cell suspension was added to the Transwell 
chamber, and the Transwell plate was cultured in a CO2 
incubator at 37 °C for 24 h. The chamber was taken out, the 
medium was washed away with PBS, and the crystal violet 
was stained for 10 min; the surface crystal crystal was washed 
away by tap water, and the cells on the inoculation side in the 
upper chamber were wiped clean with a cotton swab, and the 
non-cell inoculation side was photographed under a 
microscope. The number of transmembrane cells was 
observed and counted under a microscope, and 5 fields were 
randomly taken to obtain the mean value. 
CCK-8 assay 
MiR-382 or control miR was co-transfected into 4T1 cells 
with pCDNA3.1 or pCDNA-PGC1α, respectively, and 100 μL 
(about 10 000 cells) of cell suspension was placed in a 96-well 
culture plate, with 5 replicates in each group. The plate was 
preincubated for 48 h in an incubator to allow the cells to 
adhere. 100 μL of each group of the test substance was added 
to the culture plate. After the culture plates were intervened in 
the incubator for 6, 12, 24, and 48 h, 10 μL of CCK-8 solution 
was added to each well, and the plates were further incubated 
in an incubator. The optical density value D (450) at 450 nm 
was measured with a microplate reader. The obtained value 
can be prepared by using the number of cells as the X-axis and 
the optical density as the Y-axis. 
Subcutaneous transplantation tumor 
miR-382 or control miR was co-transfected into 4T1 cells 
with pCDNA3.1 or pCDNA-PGC-1α, respectively, and 
5×106/100 μL cell suspension was inoculated into the right 
groin of the mice, each injection of 0.2 mL ( The number of 
cells was 1×107/well), and 0.2 mL of normal saline was 
injected as a negative control under the left inguinal region. 
The tumor growth at the injection site was observed every day. 
The mouse tumor volume was measured and calculated using 
a vernier caliper. 
Statistical analysis 
Statistical processing was performed using SPSS 20.0 
software. The data were expressed as x±s, and the variance 
analysis and t-test were compared between groups.  
Results 
Effect of overexpression of miR-382 on the expression level of 
PGC-1α 
The bioinformatics online website (www.microrna.org/) 
found that there are multiple potential miR binding sites in the 
3'-UTR of mouse PGC-1α gene: mmu-miR-382, mmu-miR-  
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Figure 3. Effect of inhibition of miR-382 on the expression of PGC-1α. 
A: QT-PCR detectionof PGC-1α mRNA. *P < 0.05, compared with the 
control group; B: Western blot results shows the PGC-1α protein is 
increased in cells treated with anti-miR-382. 
 
539, mmu-miR-218, mmu-miR-202-3p, mmu-miR-451, 
mmu-miR-320, mmu-miR-375, mmu-miR-129-5p, mmu-
miR-335-5p, mmu-miR-362-3p, mmu-miR-543. The miRs of 
the top 5 predicted scores were transfected into mouse breast 
cancer cells 4T1. As shown in Fig. 1, miR-382 had the most 
significant inhibitory effect on the expression level of PGC-1α 
mRNA (0.25±0.04). The protein was collected for 48 h and 
detected by Western blot. As shown in Fig. 1, compared with 
the control group (0.33±0.05), miR-382 significantly inhibited 
the level of PGC-1α protein [(0.16±0.03), P < 0.05]. 
Inhibition of miR-382 expression on the expression of PGC-
1α 
The inhibitory probe anti-miR-382 or control miR was 
transfected into 4T1 cells, and Real-time PCR and Western 
blot were performed 48 hours later. As shown in Figure 3, anti-
miR-382 significantly up-regulated PGC-1α mRNA levels 
(0.53 ± 0.02) and protein levels (P < 0.05) compared to the 
control group (0.30 ± 0.04). 
Luciferase assay to confirm the interaction between miR-382 
and PGC-1α 
The sequence of mouse miR-382 (mmu-miR-382) is highly 
complementary to the mouse wild-type PGC-1α 3'-UTR, and 
the site of action is located at PGC-1α 3'-UTR 565-582. The 
complementary sequence is ACAACUU. The plasmid with 
the core complement was mutated into UAAAUCU, and 
 
Figure 4. Luciferase assay confirms the interaction between miR-382 
and PGC-1α and found that the PGC1αis the direct target of miR-382. 
*P < 0.05, compared to the Wild type+Control. 
the luciferase reporter gene was transfected into 293T cells. 
The results in Fig. 4 showed that miR-382 significantly 
inhibited wild-type compared to the control [relative 
luciferase activity (1.02 ± 0.11)]. The activity of the reporter 
plasmid [relative luciferase activity was (0.28 ± 0.04), P < 
0.05]; whereas in the mutant reporter plasmid group, miR-382 
had no significant inhibitory effect. 
Effect of miR-382 on the proliferation of 4T1 cells 
The miR-382 mimics or the control miR were co-
transfected into 4T1 cells with pCDNA3.1 or pCDNA-PGC1α, 
respectively, and the cell proliferation activity was detected by 
CCK-8 method, as shown in Fig. 5. At 48 hour, when 
compared with the control + pCDNA3.1 group (1.16±0.08), 
miR-382 significantly inhibited the proliferation of 4T1 cells 
in vitro [(0.65±0.05), P < 0.05]. However, the control 
+pCDNA-PGC1a (1.61±0.17) increased the proliferation of 
4T1 cells in vitro [(1.61±0.17), P < 0.05] which suggest that 
the overexpression of PGC-1α could significantly promoted 
cell proliferation and counteract the inhibitory effect of miR-
382 on PGC-1α. 
 
Figure 5. Effect of C miR-382/PGC-1α signaling pathway on 
proliferation of 4T1 cells in vitro. * P < 0.05, **P < 0.05, compared to 
the Control+pCDNA3.1. 
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Figure 6. Effect of miR-382/PGC-1α signaling pathway on migration of 
4T1 cells by transwell assay. * P < 0.05, **P < 0.05, compared to the 
Control+pCDNA3.1. 
 
Effect of miR-382 on migration ability of 4T1 cells 
As shown in Figure 6, the number of transmembrane cells 
in the control +pCDNA3.1 group was 780±97 and in the miR-
382+pCDNA3.1 group, it was 211±43), which indicate that 
miR-382 significantly inhibited the migration of 4T1 cells (P 
< 0.05). However, the number of cells in the control 
+pCDNA-PGC-1α group was 1579±132, which suggest that 
overexpression of PGC-1α significantly promoted the 
migration activity of 4T1 cells and counteracted the inhibition 
of PGC1α by miR-382.  
Effect of miR-382 on the growth of subcutaneous xenografts 
As shown in Figure 7, miR-382 mimics or control miR were 
co-transfected with 4C1 cells with pCDNA3.1 or pCDNA-
PGC1α, respectively, and a mouse subcutaneous xenograft 
model was established. On day 14, was used to show: the 
volume of transplanted tumor in control + pCDNA3.1 group 
was (0.74±0.16) cm3, and that in miR-382+pCDNA3.1 group 
was (0.29±0.12) cm3, which miR-382 significantly inhibited 
the growth of 4T1 xenografts (P < 0.05). Overexpression of 
PGC1α significantly promoted the growth of transplanted 
tumors in control+pCDNA-PGC-1α group [(1.89±0.19) cm3, 
P < 0.05]. In addition, the inhibitory effect of miR-382 was 
blocked by overexpression of PGC1α. 
 
Figure 7. Effect of miR-382 on the growth of subcutaneous xenografts. 
* P < 0.05, **P < 0.05, compared to the Control+pCDNA3.1. 
 
Discussion 
Triple-negative breast cancer is a heterogeneous disease 
with complex origin. Its occurrence and development are 
closely related to environmental and genetic factors [8], 
accounting for 15%-20% of all breast cancers. It has unique 
clinicopathological features, such as histopathological grades 
are high, easy to local recurrence, early metastasis, strong 
invasiveness, poor prognosis, etc. [9-10]. At present, with the 
continuous improvement of the level of surgery, further 
regulation of radiation therapy and chemotherapy, the 
diagnosis and treatment of breast cancer has also made great 
progress. However, distant metastasis remains a therapeutic 
bottleneck and is one of the research hotspots of breast cancer. 
This PGC-1α is one of the subtypes of the PGC-1 family 
and is a coactivator of peroxisome proliferator-activated 
receptor γ (PPARγ) [11]. The human PGC-1 gene is located 
on chromosome 4p15 and has a molecular weight of 91 kDAa. 
It was first discovered by PUIGSERVER [12] using yeast two-
hybrid technique from a cDNA library constructed from 
brown adipose tissue of mice, and ST-PIERRE et al [13] found 
that PGC -1α can effectively inhibit ROS production, promote 
mitochondrial replication and transcription, increase ATP 
production, and promote tumor cell metastasis. In breast 
cancer, patients with high plasma PGC-1α levels have a lower 
prognosis and survival rate than breast cancer patients with 
low plasma PGC-1α levels [12]. In invasive breast cancer, 
PGC-1α promotes distant metastasis of cancer cells by 
enhancing mitochondrial function [14]. However, the specific 
mechanism of upstream regulation of PGC-1α has not been 
clarified. 
We found multiple potential miR binding sites in the 3'-
UTR of the PGC-1α gene by gene online prediction software. 
miRNAs are the largest group of post-transcriptional 
regulators. MicroRNA (miRNA) is one of the post-
transcriptional regulators [15], and its 5' end binds to the 3' 
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untranslated region (3'-UTR) of the target gene, thereby 
degrading gene translation and reducing protein expression 
[16]. miRNAs are involved in a range of biological processes, 
including cell cycle, growth, apoptosis, differentiation, and 
stress response [17]. Multiple miRNAs regulate cell 
proliferation, angiogenesis, invasion, and metastasis of breast 
cancer through targeted genes. The first discovered miRNA 
associated with breast cancer was miR-206. The miR-206 was 
significantly decreased in breast cancer tissues, and the low 
miR-206 level was closely related to the late clinical stage and 
the overall overall survival rate [18]. miR-125 also inhibits 
ErBb2 by RTNK, and miR-145 also plays a role in breast 
cancer metastasis [14, 19]. Studies have shown that miR-382 
is also closely related to the development of cancer. For 
example, miR-382 is involved in the development and 
metastasis of non-small cell lung cancer by inhibiting SETD8 
expression [20]. In colorectal cancer, miR-382 regulates 
NR2F2 to promote the development of cancer [21, 22]. 
However, whether miR-382 has a targeted regulatory 
relationship with PGC-1α in breast cancer remains to be 
determined. Our previous study found that miR-382 inhibits 
the activation of aerobic oxidation-dependent M2 
macrophages in TAMs by inhibiting the expression of PGC-
1α, thereby inhibiting cancer cell metastasis [6-7]. But the 
relationship between the two in breast cancer cells is unclear. 
Therefore, this experiment first used the bioinformatics 
website to find potential binding sites for multiple miRNAs to 
PGC-1α, namely mmu-miR-382, mmu-miR-539, mmu-miR-
218, mmu-miR-202-3p, mmu-miR-451, mmu-miR-320, 
mmu-miR-375, mmu-miR-129-5p, mmu-miR-335-5p, mmu-
miR-362-3p, mmu-miR-543. Among them, miR-382 can 
significantly inhibit the expression of PGC-1α gene and 
protein, and the expression of PGC-1α is significantly 
increased after inhibiting miR-382, indicating that PGC-1α is 
regulated by miR-382, but the site of action is still unclear. We 
then constructed a PGC-1α dual luciferase reporter plasmid 
and a mutant plasmid, and co-transfected 293T cells with miR-
382 mimics to detect changes in luciferase activity. The 
principle of the luciferase reporter gene is that the miRNA acts 
mainly by acting on the 3'-UTR of the target gene, and the 3'-
UTR region of the target gene can be constructed behind the 
reporter gene Luciferase to construct a luciferase plasmid. 
Then, the cells are transfected into cells, and after comparing 
or overexpressing the miRNA, the activity of the luciferase is 
monitored, and the expression of the reporter gene is detected 
to quantitatively reflect the inhibitory effect of the miRNA on 
the target gene. This experiment found that miR-382 can 
significantly reduce the expression of luciferase activity of 
PGC-1α, and it is proved that miR-382 has a regulatory effect 
on PGC-1α, and the site of action is located at PGC-1α 3'-UTR 
565-582. 
Although we have demonstrated the regulation of PGC-1α 
by miR-382 through the above two experiments, the site of 
action is located in PGC-1α 3'-UTR 565-582, but the 
regulation of PGR-1α by miR-382 is specifically in the 
biological characteristics of breast cancer. The role of the 
aspect is still unclear, so we used pcDNA3.1 and pcDNA3.1-
PGC-1α plasmid to change the role of miR-382/PGC-1α 
signaling pathway in the proliferation, migration, 
tumorigenesis and lung metastasis of 4T1 cells. It was found 
that overexpression of miR-382 can significantly reduce the 
proliferation and migration ability of cells in vitro, and 
significantly inhibit the tumor formation and lung metastasis 
of cancer cells. Overexpression of PGC-1α can significantly 
increase the proliferation and migration ability of cells in vitro, 
and significantly promote tumor formation and lung 
metastasis. 
In conclusion, miR-382 may inhibit the proliferation and 
lung metastasis of 4T1 cell line by PGC-1α, and its site of 
action is located at the PGC-1α 3'-UTR 565-582.  
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